• Salesforce recently announced that the U.S. Department of Veterans Affairs awarded it a three-year Agentic Enterprise License Agreement worth up to US$1.60 billion to modernize care and service delivery with Missionforce and AI agents across its nationwide healthcare and benefits network.
• This contract deepens Salesforce’s role in federal healthcare technology while spotlighting its Agentforce and Missionforce platforms as core tools for AI-driven workflow modernization in highly regulated public-sector environments.
• Next, we’ll consider how this large VA AI modernization deal could reshape Salesforce’s investment narrative around agentic automation.

We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Salesforce Investment Narrative Recap

To own Salesforce, you need to believe it can turn its AI and data platforms into stickier, higher value relationships across its massive customer base. The VA’s US$1.60 billion Agentic Enterprise License Agreement reinforces that agentic automation in complex, regulated settings is a key near term catalyst, while competitive pressure from hyperscalers bundling AI and CRM remains a central risk that this deal does not fully resolve.

Among recent announcements, the expansion with CVS Health using Agentforce Health in highly regulated healthcare settings feels closest to the VA win. Together, they underline Salesforce’s push to make Agentforce and Missionforce the backbone of AI assisted workflows in sectors where compliance, security, and reliability are non negotiable, which ties directly into the catalyst of deeper customer lock in and higher switching costs.

Yet behind the VA win, investors should be aware of how rising data privacy and public sector compliance demands could…

Salesforce's narrative projects $56.7 billion revenue and $10.3 billion earnings by 2029.

Uncover how Salesforce's forecasts yield a $241.72 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Before the VA contract, the most bullish analysts were already assuming revenue around US$59.8 billion and earnings near US$11.7 billion by 2029, presenting a far more optimistic picture than consensus and your chosen concern about regulatory and public sector expansion risks, so this new deal may shift those narratives in very different directions.

Explore 26 other fair value estimates on Salesforce - why the stock might be worth just $221.16!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Salesforce research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Salesforce research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Salesforce's overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.